Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | BIT:1BIIB | Italy | Ordinary Share |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 146.95 | 0.00 | 16:34:35 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 152.05 | 152.70 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | USD 9.84B | USD 1.16B | USD 7.9681 | 19.82 | 21.41B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | 146.95 | EUR |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/11/2024 | 06:00 | UKREG | Dapirolizumab Pegol Phase 3 Data Presented at the American College of.. |
| 14/11/2024 | 16:23 | UKREG | Eisai Receives Positive Opinion from the CHMP in the European Union for.. |
| 30/10/2024 | 23:30 | UKREG | Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting.. |
| 29/10/2024 | 22:00 | UKREG | Biogen and Neomorph Announce Multi-Target Research Collaboration to.. |
| 29/10/2024 | 12:00 | UKREG | Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer |
| 28/10/2024 | 12:30 | UKREG | Michael McDonnell, Executive Vice President and Chief Financial Officer to.. |
| 27/10/2024 | 00:15 | UKREG | Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in.. |
| 24/10/2024 | 11:30 | UKREG | Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease.. |
| 22/10/2024 | 11:30 | UKREG | Biogen Announces Late Breaker and New Data Presentations at American.. |
| 09/10/2024 | 11:30 | UKREG | Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab.. |
Biogen (1BIIB) Share Charts1 Year Biogen Chart |
|
1 Month Biogen Chart |
Intraday Biogen Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
